- Trial phase
- Phase 3
- Time to market
- Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
- Why 4/10
- No hard dated binary catalyst in the next ~12 months. Part 2 of the ProstACT Global Phase 3 trial (~490-patient randomized expansion) is enrolling but is an event-driven rPFS study, readout is likely 2027+. No PDUFA or US filing yet. TLX591-Tx is Telix's lead therapeutic candidate, but the company already generates ~$800M+ annual revenue from approved imaging products (Illuccix, Gozellix), making this a non-binary asset for a multi-product commercial-stage company.
Watch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.
Price Chart
Executive Summary
TLX591-Tx (lutetium-177 rosopatamab tetraxetan) is Telix Pharmaceuticals' lead therapeutic candidate, a first-in-class PSMA-targeted radio antibody-drug conjugate (rADC) for metastatic castration-resistant prostate cancer (mCRPC). It is currently in a global Phase 3 trial (ProstACT Global) with Part 1 safety data successfully presented at ASCO 2026 and Part 2 (randomized, ~490 patients) now enrolling. Unlike its competitor Novartis' Pluvicto (a small-molecule radioligand), TLX591-Tx uses an antibody-based approach that Telix says offers prolonged tumor retention, a patient-friendly two-dose regimen, and significantly lower manufacturing costs. The drug has no imminent regulatory catalyst, Part 2 is an event-driven rPFS study with readout likely in 2027+, and Telix is already a commercial-stage company generating ~$804M in FY2025 revenue from approved imaging products (Illuccix, Gozellix). CEO Behrenbruch purchased ~$1M of stock in April 2026, and major institutions (FMR, Morgan Stanley, BlackRock) doubled positions in Q1 2026.
How It Works
A targeted radiation therapy for advanced prostate cancer. TLX591-Tx is a "radio antibody-drug conjugate" (rADC), an antibody (rosopatamab) designed to seek out and bind to PSMA, a protein found on prostate cancer cells. Attached to the antibody is a small radioactive payload (lutetium-177) that delivers localized radiation directly to the tumor cells, killing them while largely sparing healthy tissue. Unlike Novartis' Pluvicto (a small-molecule approach), TLX591-Tx uses a larger antibody that stays in the tumor longer, potentially enabling a shorter, more convenient two-dose regimen.
Trial Status
Part 1 (safety/dosimetry lead-in, 36 patients) of the ProstACT Global Phase 3 study completed and met primary objectives, acceptable safety and tolerability with no new safety signals. Data presented as a late-breaking oral at ASCO 2026 (June 2026). Part 2 (2:1 randomized treatment expansion, ~490 patients) has begun enrolling in Australia, New Zealand, and Canada, with US sites pending FDA alignment. Primary endpoint is radiographic progression-free survival (rPFS).
The Two-Sided Case
Upcoming Catalysts
- ProstACT Global Part 2 enrollment updates (ongoing, ~490-patient target)
- FDA alignment for US enrollment in Part 2 (recently announced alignment on Part 1 safety data)
- Any potential interim analysis from the event-driven Part 2 (timing uncertain)
- Pixclara (TLX101-CDx) PDUFA date for brain cancer imaging, a separate near-term Telix catalyst
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Telix Pharmaceuticals Limited Press Release TLX ·Originating report